Ann: Patrys - Details of PAT-SM6 & Carfilzomib Clinical Trial, page-5

Patience, all. The relevant context is that average time from the first clinical trial to approval for sale is about eight years, give or take. Orphan drug status was a great accelerator in our case, and of course most here hope that a cash-out point will be reached somewhere along the line without having to stay the whole course. But if you are in this to get your golden egg tomorrow, look elsewhere. As to management, if there's nothing to report, there's little point in reporting it! That doesn't make them poor managers.